dolutegravir
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus
Conditions
Infection, Human Immunodeficiency Virus
Trial Timeline
May 1, 2011 → May 1, 2015
NCT ID
NCT01328041About dolutegravir
dolutegravir is a phase 3 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01328041. Target conditions include Infection, Human Immunodeficiency Virus.
What happened to similar drugs?
20 of 20 similar drugs in Infection, Human Immunodeficiency Virus were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01499199 | Phase 3 | Completed |
| NCT01328041 | Phase 3 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1944 | Moderna | Phase 1 | 0 |
| mRNA-1189 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1653 | Moderna | Phase 1 | 0 |
| mRNA-1195.1 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 3 | 0 |
| DFA-02 Antibiotic Gel + DFA-02 Placebo Gel | Dr. Reddy's Laboratories | Phase 2 | 32 |
| DFA-02 + Placebo | Dr. Reddy's Laboratories | Phase 1/2 | 29 |
| Levofloxacin + Levofloxacin | Dr. Reddy's Laboratories | Approved | 36 |
| BSG005 | Alkem Laboratories | Phase 1/2 | 39 |
| Zotatifin + Placebo | eFFECTOR Therapeutics | Phase 1 | 19 |
| AAVLP-HPV + Placebo | 2A Pharma | Phase 1 | 19 |
| CT-P59 | Celltrion | Phase 1 | 29 |
| CT-P63 + Placebo | Celltrion | Phase 1 | 29 |